Strategies to Enhance the Hepatitis C Care Cascade Among People Who Inject Drugs
|
|
- Samson Gilbert
- 5 years ago
- Views:
Transcription
1 Strategies to Enhance the Hepatitis C Care Cascade Among People Who Inject Drugs Jason Grebely, PhD Associate Professor Viral Hepatitis Clinical Research Program The Kirby Institute UNSW Australia
2 Disclosures Consultant/advisor for and has received research grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck/MSD
3 Strategies to Enhance the HCV Care Cascade Among PWID Issues The burden of HCV infection is growing, including among PWID HCV treatment is effective among PWID HCV testing, assessment and treatment uptake remain low Simple, tolerable, effective therapies are a game changer Strategies to enhance HCV testing/treatment among PWID Treatment as prevention
4 Defining populations of PWID L I F E T I M E P W I D C U R R E N T P W I D P W I D I N O S T 1) Larney S, et al. Int J Drug Policy ) Grebely J et al. Int J Drug Policy 2015.
5 The HCV care cascade 1) Grebely J et al. Int J Drug Policy 2015.
6 Enhancing HCV testing and diagnosis of active infection 1) Grebely J et al. Int J Drug Policy 2015.
7 Successful strategies to increase HCV testing/diagnosis Targeted case-finding 2 Risk-based assessment 3,4 Hepatitis Care Coordination with case management 5 Free counseling and testing 6 Dried blood spot testing 7 Point-of-care testing 6 1) Meyer J, Int J Drug Policy ) Cullen B Am J Pub Health ) Drainoni M. Am J Pub Health ) Litwin A Dig Dis Sci ) Masson C, Am J Pub Health ) Morano J, J Comm Health ) Coats J, Int J Drug Pol 2015.
8 Successful strategies to increase HCV testing/diagnosis Targeted case-finding 2 Risk-based assessment 3,4 Hepatitis Care Coordination with case management 5 Free counseling and testing 6 Dried blood spot testing 7 Point-of-care testing 6 1) Meyer J, Int J Drug Policy ) Cullen B Am J Pub Health ) Drainoni M. Am J Pub Health ) Litwin A Dig Dis Sci ) Masson C, Am J Pub Health ) Morano J, J Comm Health ) Coats J, Int J Drug Pol 2015.
9 Assay Analyte Sample Simplification of strategies to increase HCV testing Plasma WB Venepuncture Capillary Drop DBS RNA Core Ag Point of care Centralised
10 Enhancing diagnoses: DBS in drug services in Scotland
11 On-line self-collected DBS 1. Order online 2. DBS kit delivered 3. Self sample 4. Post to lab 9. Referral to care 8. Phone call + 7. Reactive? 5. Central lab test HIV testing in comparison with STI clinics (UK) Equal recruitment, return results, and reactivity DBS covered broader geographic area Diagnosed higher number of African American heterosexual men Terrence Higgins Trust. Public Health England. 56 Dean St.
12 Enhancing diagnoses: POC testing Mobile medical clinic (n=1345) Accepted HCV testing N=438 (33%) 48% selected POC testing 52% selected phlebotomy 94% linked to HCV care 18% linked to HCV care P<0.001 Morano J, J Comm Health 2014.
13 Enhancing diagnoses: POC HCV RNA testing GeneXpert PCR-based portable system Test results in 100 min RNA confirmation in one visit 1) Cepheid. Product Information.
14 GeneXpert (Cepheid) POC test for HCV Minivette capillary tube Xpert machine Laptop Finger-prick Single-use test cartridge Xpert cartridge
15 Diagnostic models of care Sexual health Drug and alcohol clinics NSP services Community health centres Clinics Small labs Primary health care / GPs Prisons Central lab Centralised Decentralised
16 Cohn et al Curr Opinio. Simplified diagnostic monitoring for hepatitis C in the new era of directly acting antivirals. Simplified monitoring Treatment Viral recurrence <12 weeks Treatment 4wk 8wk EOT SVR12 SVR24 Current HCV diagnostics Ab Gt VL Fibrosis VL VL VL VL Simplified diagnostics Qual RNA +Fibrosis Qual RNA Self collected DBS kit
17 Enhancing linkage to care and liver disease assessment 1) Grebely J et al. Int J Drug Policy 2015.
18 Enhancing linkage to care: FibroScan -based screening/assessment Social marketing to inform campaign resources Implementation phase: four clinics; one day per week for four weeks (with peer-based support), with subsequent clinical follow-up 95% reported that FibroScan was acceptable 60% returned for post-fibroscan assessment by a nurse/specialist Marshall A, et al. Int J Drug Policy 2015.
19 Enhancing linkage to care: Hepatitis care coordination RCT of participants attending OST clinics (n=489) Intervention arm received on-site screening, enhanced education and counseling, and case management services Those receiving intervention more likely to be linked to care 6-months post-follow-up (OR = 4.10; 95% CI = 2.35, 7.17) Masson C, et al. Am J Pub Health 2013.
20 Enhancing linkage to care: Multiple models of HCV care One size does not fit all Drug and alcohol clinics Primary health care/gp centres Tertiary care M o d e l s o f H C V C a r e Prisons Harm reduction drop-in centres Community health centre Bruggmann P and Litwin A Clinical Infectious Diseases 2013.
21 Enhancing HCV treatment and cure 1) Grebely J et al. Int J Drug Policy 2015.
22 Treatment outcomes: History of injecting - PEG-IFN/RBV 56% (95% CI, 51%, 60%) Dimova R, et al Clinical Infectious Diseases 2013
23 Treatment outcomes: Active injecting - PEG-IFN/RBV 56% (95% CI, 50%, 61%) Aspinall E, et al Clinical Infectious Diseases 2013
24 EFFICACY 3 years 20 years PEG-IFN/RBV/SOF PEG-IFN/RBV/SMV SOF/SMV SOF/LDV PTV/OBV/DSV/RBV SOF/DCV PEG-IFN/RBV/TVR PEG-IFN/RBV/BOC PEG-IFN/RBV 48 WEEKS WEEKS IFN/RBV 24 WEEKS 12 WEEKS IFN TOLERABILITY Dore GJ & Feld J. CID 2015
25 HCV life cycle: targets for antiviral therapy Polyprotein Translation Protease Inhibitors NUCLEUS Protease Cleavage LDL-R NS5A Inhibitors NS5A Replication Complex SRB 1 CD8 1 RNA Uncoating CLDN1 OCLN Membranous Web Polymerase RNA Inhibitors Replication RdRp Viral Assembly Viral Release Dore and Feld CID 2015
26 IFN-free Genotype Naïve (12 wks) Exp (12 wks) Naïve (8 wks) 70 SVR12 % SOF/LED PTV/OBV/DSV/RBV GZR/EBR SOF/SMV 26 Zeuzem, NEJM 2014; Afdhal, NEJM 2014; Kowdley, NEJM 2014; Feld, NEJM 2014; Zeuzum, ILC 2015; Kwo, ILC 2015
27 IFN-free HIV infection GT1, treatment naïve, F0-4; 12 weeks duration HCV HIV/HCV SVR12 % /70 54/56 SOF/LED PTV/OBV/DSV/RBV SOF/DCV GZR/EBR Afdhal, NEJM2014; Naggie, CROI2015; Feld, NEJM2014; Rockstroh, WAC2014; Wyles, CROI2015; Zeuzem, ILC2015; Rockstroh, ILC2015; Poordad, ILC2015
28 IFN-free OST GT1, treatment naïve, F0-4; 12 weeks duration Non-OST OST 70 SVR12 % /70 54/56 SOF/LDV PTV/OBV/DSV/RBV GZR/EBR 184/ Afdhal, NEJM 2014; Feld, NEJM 2014; Lalezari, IAC 2015; Zeuzem, ILC 2015; Jacobson, AASLD 2014; Dore AASLD 2015.
29 IFN-free OST GT1, treatment naïve, F0-4; 12 weeks duration Non-OST OST 70 SVR12 % /70 54/56 SOF/LDV PTV/OBV/DSV/RBV GZR/EBR 189/ Afdhal, NEJM 2014; Feld, NEJM 2014; Lalezari, IAC 2015; Zeuzem, ILC 2015; Jacobson, AASLD 2014; Dore AASLD 2015
30 Elbasvir/Grazoprevir: C-EDGE CO-STAR study Phase 3, randomized, parallel-group, placebo-controlled, double-blind trial Treatment naïve, GT1, 4, 6; mixed genotypes of 1, 4, and 6 allowed On opiate substitution therapy (OST) for at least 3 months and consistently kept at least 80% of scheduled appointments while on OST Goal of 20% with cirrhosis and may be co-infected with HIV Immediate Treatment Arm EBR / GZR, n = 201 Unblinding Follow-up for 24 weeks Deferred Treatment Arm Placebo, n = 100 Unblinding EBR / GZR, n=100 Follow-up for 24 weeks D1 W4 W8 W12 W16 W22 W28 W36 W52 Dore GJ, et al. AASLD 2015.
31 % SVR12 (95% CI) SVR - Immediate Treatment Group Full analysis set All GT GT1a* GT1b GT4 GT6 mfas 184/ /154 28/30 11/12 1/5 189/198 Relapse Reinfection LTFU or discontinued unrelated to VF (excluded) *Includes one subject with mixed infection (GT1a and GT1b) who achieved SVR12 Includes one subject with HCV RNA>LLoQ consistent with reinfection; this subject was lost to follow-up and did not return for confirmation of HCV RNA; this subject was discontinued for administrative reason and counted as a failure in the FAS, GT = genotype; LTFU = lost to follow-up; VF=virologic failure Dore GJ, et al. AASLD 2015.
32 % SVR12 (95% CI) SVR - Immediate Treatment Group Modified analysis set All GT GT1a* GT1b GT4 GT6 189/ /153 28/29 11/11 3/5 Failures Relapse Discontinuation Reinfection counted as success LTFU or discontinued unrelated to Virologic Failure excluded from mfas analysis *Includes one subject with mixed infection (GT1a and GT1b) who achieved SVR12 Dore GJ, et al. AASLD 2015.
33 Factors associated with SVR12 Dore GJ, et al. AASLD 2015.
34 % Adherence Adherence to therapy >80% (>67 doses) >90% (>76 doses) >95% (>79 doses) Immediate treatment arm Deferred treatment arm Dore GJ, et al. AASLD 2015.
35 % Adherence Adherence to therapy across Phase III program >90% (>76 doses) CO-STAR (n=201) Co-Infection (n=218) Treatment-Naïve (n=316) Dore GJ, et al. AASLD 2015.
36 Urinary Drug Screen: baseline and on-treatment 66/70 54/56 184/201 Dore GJ, et al. AASLD 2015.
37 Adverse events 25 ELB/GZR (n=201) 20 PBO (n=100) /70 54/56 184/201 Fatigue Headache Nausea Serious AE Discontinue Deaths Dore GJ, et al. AASLD 2015.
38 Sofosbuvir-based therapy among recent PWID PWID with G1-4 attending OST clinics and receiving sofosbuvir-based regimens with ribavirin or PEG-IFN/ribavirin (n=61) Blister-pack for adherence monitoring 61% with drug use at baseline and 51% with drug use during treatment Overall SVR was 80% (vs. expected of 85%) Litwin A, et al. INHSU 2015, Sydney, Australia.
39 Restricting HCV treatment access to PWID in the US Barua S, et al Ann Int Med 2015
40 Sofosbuvir/velpatisvir GT1-6, treatment naïve and exp. (28%), F0-4 (21% F4), 12 wks SVR12 % /41 11/11 18/30 24/30 5/11 323/ /215 66/70 237/ / / /216 54/56 116/ /214 34/35 211/217 41/41 100/101 31/47 GT1 GT2 GT3 GT4 GT5 GT6 Feld JJ, et al. NEJM 2015; Foster GR, et al. NEJM 2015
41 Restricting HCV treatment access to PWID in the US AASLD/IDSA HCV treatment guidelines Recent and active IDU should not be seen as an absolute contraindication to HCV therapy. Scale up of HCV treatment in persons who inject drugs is necessary to positively impact the HCV epidemic in the United States and globally.
42 Recommendations for HCV management in PWID Grebely, et al. Int J Drug Policy. 2015
43 Restricting HCV treatment access in the US Liver disease stage Barua S, et al Ann Int Med 2015
44 Australia one of the first countries to make access for all public health policy May 2015: Access for all to highly effective HCV treatment a priority Dec 20, 2015: $1 billion for HCV treatment over 5 years ( )
45 Adherence to therapy is key.. Litwin A, et al. INHSU 2015, Sydney, Australia.
46 Enhancing treatment and cure: Adherence
47 % HCV reinfections after 5 years Education about reinfection risk is crucial 25 Low-risk 24 studies n=6,046 Avg. FU=4.1 years PWID / prisoners 16 studies n=1,203 Avg. FU=5.0 years HIV co-infected 10 studies n=1,106 Avg. FU=3.1 years 24% % 5 1% 0 Simmons CID 2016 Low risk PWID / prisoner HIV co-infected
48 Can HCV treatment play a role in prevention? Martin N, et al. Hepatology 2013.
49 Can HCV treatment play a role in prevention? Melbourne Martin N, et al. Hepatology 2013 In Press.
50 Settings for HCV TasP Community-based PWID 88K 50K 24K PWID with Chronic HCV Grebely J and Dore GJ Antiviral Research 2014.
51 Settings for HCV TasP Drug and alcohol 88K 50K 12K 24K PWID with Chronic HCV PWID on OST Grebely J and Dore GJ Antiviral Research 2014.
52 Settings for HCV TasP Prisons 88K 10K 50K 12K 24K PWID with Chronic HCV PWID on OST Prisoners (per year) Grebely J and Dore GJ Antiviral Research 2014.
53 Nurse-led model of care Clinical Nurse Consultants Post-test counselling: chronic HCV Protocol-driven investigations Focused history & examination Triage decision Specialist Category A: Discussion & Rx prescription Category B: Teleconference with patient & Rx prescription Category C: Face-to-face review & Rx prescription Clinical Nurse Consultants Treatment Lloyd A et al. Clinical Infectious Diseases 2013
54 OCT Prison-based HCV TasP for PWID Primary Objective To evaluate the impact of a rapid scale-up of IFN-free HCV treatment on HCV transmission Primary Endpoint Change in HCV incidence from pre- to post- scale-up of IFN-free HCV treatment ENROLMENT OPEN STUDY CLOSE HCV INCIDENCE AND PREVALENCE SURVEILLANCE INTERFERON-FREE DAA THERAPY subjects 550+ subjects TRANSLATIONAL RESEARCH
55 Prison-based HCV TasP for PWID Lithgow Correctional Centre Lithgow Outer Metropolitan Multipurpose Correctional Centre Sydney Dillwynia (Womens) Correctional Centre Sydney Goulburn Correctional Centre Goulburn
56 Prison-based HCV TasP for PWID HCV incidence and prevalence phase 6-monthly testing and risk behaviour interview (n=359/1,200) Chronic HCV prevalence = 27% Treatment phase DAA therapy for all infected prisoners (sofosbuvir/velpatasvir) Modelling Treatment sample size and epidemiological impact Cost-effectiveness and budget impact Is DAA therapy in prisons good value for money and can we afford it? Qualitative research Patient, provider, staff and policy-maker attitudes & barriers towards DAA therapy Implementation toolkit How can DAA therapy be scaled up across NSW and nationally?
57 NSP and OST required to optimize TasP Martin NK, et al. Clinical Infectious Diseases 2013.
58 Lima PLOS ONE 2015 NSP and OST required to optimize TasP
59 Global NSP coverage is limited Only 41% (n=82) of countries had implemented NSPs Mathers B, et al. Lancet 2010
60 Secondary Infections Need to scale-up HCV therapy quickly to avert reinfection ,500 3,000 2,500 2,000 1,500 1, Annual Number Treated Treat 1% Treat 2% Treat 4% Treat 8% Treat 10% Treat 1% Treat 2% Treat 4% Treat 8% Treat 10% Razavi INHSU 2015, Sydney, Australia, Oct 7-9, 2015
61 HCV test and treat among PWID Increase screening/diagnosis Strategies for enhanced HCV RNA testing (DBS testing and POC RNA) Increase linkage to care and treatment Expanded access to non-invasive tools for staging (Fibroscan) Expanded models of care to engage and treat HCV among PWID Increase treatment response and cure Expanded access to IFN-free therapies among PWID Who will require optimized adherence strategies? Weekly DOT, blister packs, text messaging, mobile apps, etc. Prevention of reinfection Treatment as prevention?
62 Acknowledgements UNSW Australia Prof. Gregory Dore Prof. Andrew Lloyd Dr. Behzad Hajarizadeh Prof. Carla Treloar Prof. Tony Butler International Collaborators Prof. Alain Litwin (US) A/Prof. Natasha Martin (US) Prof. Peter Vickerman (UK) Prof. Matt Hickman (UK) A/Prof. Viviane Dias Lima (Canada) Prof. Julio Montaner (Canada) Dr. Lynn Taylor (US) Dr. Homie Razavi (US)
63
Will HCV therapies deliver global impact? Professor Greg Dore
Will HCV therapies deliver global impact? Professor Greg Dore Disclosures Gregory Dore has received research grants awarded to his institution from Gilead, Bristol Myers Squibb, Abbvie, Merck, and Janssen;
More informationHCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews
HCV: how do we reach elimination from a clinicians perspective A/Professor Gail Matthews WHO global hepatitis elimination goals by 2030 Elimination a reduction in HCV incidence and HCVrelated mortality
More informationDAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination
DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination Associate Professor Jason Grebely HEP DART 2017, Kohala Coast, Hawaii, 3 rd December 2017 Disclosures
More informationHCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore
HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore Disclosures Research grants, travel support, and honoraria: AbbVie, Gilead, Merck HCV screening in Australia
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationRECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J
More informationSurveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015
Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Professor Andrew Lloyd Wednesday 7 th October 2015 Australian prison population 30,775 5% 34 92% Total population Increase from 2012 Median
More informationUpdate in hepatitis C virus infection
Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward
More informationHIV/Sexual Health Clinical Education Session.
HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in
More informationTreatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017
Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017 Conflicts of interest Receive
More informationThe single tablet regimen of ledipasvir/sofosbuvir is efficacious and well-tolerated among people receiving opioid substitution therapy
The single tablet regimen of ledipasvir/sofosbuvir is efficacious and well-tolerated among people receiving opioid substitution therapy Reau N 1, Grebely J 2, Mauss S 3, Brown A 4, Puoti M 5, Wyles D 6,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationWe know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment
We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment Associate Professor Jason Grebely National Drug & Alcohol Research Centre, Sydney, Australia, 17 th May 2018
More informationCURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS
CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory
More informationHepatitis C Elimination: Australia s progress
Hepatitis C Elimination: Australia s progress Margaret Hellard Burnet Institute, Melbourne Disclosures I receive fellowship support from the National Health and Medical Research Council (Australia). The
More informationAustralasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely
More informationEfficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study
Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study Olav Dalgard Professor dr med Akershus University Hospital
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationTreatment as prevention in HCV: Modelling impact among people who inject drugs and HIV+ men who have sex with men
Treatment as prevention in HCV: Modelling impact among people who inject drugs and HIV+ men who have sex with men Natasha Mar)n, Peter Vickerman, Ma/ Hickman School of Social and Community Medicine, University
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationNew combination EBR/GZR: The end of an era for the difficult to treat?
New combination EBR/GZR: The end of an era for the difficult to treat? Ioannis Goulis Associate Professor in Gastroenterology Aristotle University of Thessaloniki, Greece 9 th International Congress of
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationDeveloping the campaign
Liver Disease Burden and Clinical Follow-Up During a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The LiveRLife Study Grebely J 1,
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationStable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study
Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, 2005-2014: the HITS-p study Evan B. Cunningham 1, Brigid Betz-Stablein 2, Neil A. Bretana 2, Gregory J. Dore
More informationUtility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationUpdate on HCV Treatment
Update on HCV Treatment Ajay Bharti, MD Associate Professor of Medicine Division of Infectious Diseases University of California San Diego 2018 April 28, 2018 Clinically relevant questions in HCV-HIV coinfected
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationSetting the Stage Key Challenges in Elimination
Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationSection 7: Providing HCV testing and treatment to people who inject drugs
Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationin chronic hepatitis C in Australia
Real world efficacy of antiviral therapy in chronic hepatitis C in Australia Issue #2 July 2018 1 Uptake and outcomes of new treatment for chronic hepatitis C during 20-20 in the REACH-C network The REACH-C
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHepatitis C epidemiology, screening and treatment
Hepatitis C epidemiology, screening and treatment Date Presenter Wednesday 29 August 2018: 7.00-8.00pm Professor Greg Dore This education activity has been developed in association with: Kirby Institute,
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationACKNOWLEDGEMENTS. This study was funded by Merck & Co., Inc.
C-EDGE CO-STAR: ADHERENCE AND DRUG USE IN HCV- INFECTED PERSONS ON OPIOID AGONIST THERAPY RECEIVING ELBASVIR / GRAZOPREVIR FIXED DOSE COMBINATION FOR 12 WEEKS Dore GJ 1,2 Grebely J 1, Altice F 3, Litwin
More informationModeling what is required to prevent HIV and HCV among people who inject drugs in the U.S.
Modeling what is required to prevent HIV and HCV among people who inject drugs in the U.S. Natasha K Martin, DPhil Associate Professor Division of Infectious Diseases and Global Health, University of California
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationMonitoring hepatitis C treatment uptake in Australia
Monitoring hepatitis C treatment uptake in Australia Issue #7 July 217 1 Initiations of new treatment for chronic hepatitis C in 216 An estimated 32,4 individuals initiated direct acting antiviral (DAA)
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationEliminating Hepatitis C by 2030 Enhancing Prevention, Care and Treatment Among People who Inject Drugs
Eliminating Hepatitis C by 2030 Enhancing Prevention, Care and Treatment Among People who Inject Drugs Professor Margaret Hellard Disclosures I receive fellowship support from the National Health and Medical
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationHepa%%s C elimina%on needs involvement of all turn the page. Graham R Foster Professor of Hepatology Queen Mary University of London
Hepa%%s C elimina%on needs involvement of all turn the page Graham R Foster Professor of Hepatology Queen Mary University of London Conflicts of Interest Speaker and consultancy fees received from AbbVie,
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHepatitis C Elimination Program Georgia
Hepatitis C Elimination Program Georgia Maia Butsashvili, MD, MS, PhD Health Research Union (HRU)/Clinic NEOLAB National HCV Committee International School of Public Health High prevalence of HCV in Georgia
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHIV and HCV coinfection - Barriers in Central and Eastern Europe
HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical
More informationRapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationCases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure
Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts
More informationDogma: HCV treatment for eradication. Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015
Dogma: HCV treatment for eradication Lisa Barrett MD PhD FRCPC Dept. of Infectious Diseases, Microbiology and Immunology April 18, 2015 Disclosures Some discussion of non-hc approved compounds Industry:
More informationHCV prevention amongst injecting drug users
HCV prevention amongst injecting drug users Peter Vickerman, Natasha Martin, Hannah Woodall, Katy Turner, Lucy Platt, Matthew Hickman University of Bristol MAIN INTERVENTIONS Needle and syringe provision
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationRecommendations for the Management of HCV infection: Australian (and International) Guidelines
Recommendations for the Management of HCV infection: Australian (and International) Guidelines Professor Alex Thompson St Vincent s Hospital Melbourne 30 th September 2016 1 Acknowledgement to Country
More informationHepatitis C Highlights from ILC / EASL 2016
Hepatitis C Highlights from ILC / EASL 2016 VIII International Update Workshop in Hepatology Curitiba, 26.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationTransmission. Transmission Counseling
Learning Objectives Upon completion, participants should be able to: Outline critical components of comprehensive care for patients with chronic HCV infection Counsel patients about reasonable expectations
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More information29/09/2014. Expanding access to hepatitis C treatment through primary care: Challenges and opportunities. Disclosures
2013 Viremic Cases 29/09/2014 Expanding access to hepatitis C treatment through primary care: Challenges and opportunities Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent s Hospital,
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More information